These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1143 related articles for article (PubMed ID: 17173447)

  • 1. Phenylazo-pyridine and phenylazo-pyrazole chlorido ruthenium(II) arene complexes: arene loss, aquation, and cancer cell cytotoxicity.
    Dougan SJ; Melchart M; Habtemariam A; Parsons S; Sadler PJ
    Inorg Chem; 2006 Dec; 45(26):10882-94. PubMed ID: 17173447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chloro half-sandwich osmium(II) complexes: influence of chelated N,N-ligands on hydrolysis, guanine binding, and cytotoxicity.
    Peacock AF; Habtemariam A; Moggach SA; Prescimone A; Parsons S; Sadler PJ
    Inorg Chem; 2007 May; 46(10):4049-59. PubMed ID: 17441712
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The contrasting chemistry and cancer cell cytotoxicity of bipyridine and bipyridinediol ruthenium(II) arene complexes.
    Bugarcic T; Habtemariam A; Stepankova J; Heringova P; Kasparkova J; Deeth RJ; Johnstone RD; Prescimone A; Parkin A; Parsons S; Brabec V; Sadler PJ
    Inorg Chem; 2008 Dec; 47(24):11470-86. PubMed ID: 19007206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tuning the hydrolytic aqueous chemistry of osmium arene complexes with N,O-chelating ligands to achieve cancer cell cytotoxicity.
    Peacock AF; Parsons S; Sadler PJ
    J Am Chem Soc; 2007 Mar; 129(11):3348-57. PubMed ID: 17319668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ruthenium(II) arene anticancer complexes with redox-active diamine ligands.
    Bugarcic T; Habtemariam A; Deeth RJ; Fabbiani FP; Parsons S; Sadler PJ
    Inorg Chem; 2009 Oct; 48(19):9444-53. PubMed ID: 19780621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New cytotoxic and water-soluble bis(2-phenylazopyridine)ruthenium(II) complexes.
    Hotze AC; Bacac M; Velders AH; Jansen BA; Kooijman H; Spek AL; Haasnoot JG; Reedijk J
    J Med Chem; 2003 Apr; 46(9):1743-50. PubMed ID: 12699392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tuning the reactivity of osmium(II) and ruthenium(II) arene complexes under physiological conditions.
    Peacock AF; Habtemariam A; Fernández R; Walland V; Fabbiani FP; Parsons S; Aird RE; Jodrell DI; Sadler PJ
    J Am Chem Soc; 2006 Feb; 128(5):1739-48. PubMed ID: 16448150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coordination of 9-ethylguanine to the mixed-ligand compound alpha-[Ru(azpy)(bpy)Cl2] (azpy = 2-phenylazopyridine and bpy = 2,2'-bipyridine). An unprecedented ligand positional shift, correlated to the cytotoxicity of this type of [RuL2Cl2] (with L = azpy or bpy) complex.
    Hotze AC; van der Geer EP; Caspers SE; Kooijman H; Spek AL; Haasnoot JG; Reedijk J
    Inorg Chem; 2004 Aug; 43(16):4935-43. PubMed ID: 15285670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-activity relationships for cytotoxic ruthenium(II) arene complexes containing N,N-, N,O-, and O,O-chelating ligands.
    Habtemariam A; Melchart M; Fernandez R; Parsons S; Oswald ID; Parkin A; Fabbiani FP; Davidson JE; Dawson A; Aird RE; Jodrell DI; Sadler PJ
    J Med Chem; 2006 Nov; 49(23):6858-68. PubMed ID: 17154516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis, characterization, and in vitro evaluation of novel ruthenium(II) eta6-arene imidazole complexes.
    Vock CA; Scolaro C; Phillips AD; Scopelliti R; Sava G; Dyson PJ
    J Med Chem; 2006 Sep; 49(18):5552-61. PubMed ID: 16942028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chlorido-, aqua-, 9-ethylguanine- and 9-ethyladenine-adducts of cytotoxic ruthenium arene complexes containing O,O-chelating ligands.
    Melchart M; Habtemariam A; Parsons S; Sadler PJ
    J Inorg Biochem; 2007 Nov; 101(11-12):1903-12. PubMed ID: 17582501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dichlorobis(2-phenylazopyridine)ruthenium(II) complexes: characterisation, spectroscopic and structural properties of four isomers.
    Velders AH; van der Schilden K; Hotze AC; Reedijk J; Kooijman H; Spek AL
    Dalton Trans; 2004 Feb; (3):448-55. PubMed ID: 15252553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bipyrimidine ruthenium(II) arene complexes: structure, reactivity and cytotoxicity.
    Betanzos-Lara S; Novakova O; Deeth RJ; Pizarro AM; Clarkson GJ; Liskova B; Brabec V; Sadler PJ; Habtemariam A
    J Biol Inorg Chem; 2012 Oct; 17(7):1033-51. PubMed ID: 22791215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ferrocenoyl pyridine arene ruthenium complexes with anticancer properties: synthesis, structure, electrochemistry, and cytotoxicity.
    Auzias M; Therrien B; Süss-Fink G; Stepnicka P; Ang WH; Dyson PJ
    Inorg Chem; 2008 Jan; 47(2):578-83. PubMed ID: 18085776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Derivation of structure-activity relationships from the anticancer properties of ruthenium(II) arene complexes with 2-aryldiazole ligands.
    Martínez-Alonso M; Busto N; Jalón FA; Manzano BR; Leal JM; Rodríguez AM; García B; Espino G
    Inorg Chem; 2014 Oct; 53(20):11274-88. PubMed ID: 25302401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of chelating ligands to tune the reactive site of half-sandwich ruthenium(II)-arene anticancer complexes.
    Fernández R; Melchart M; Habtemariam A; Parsons S; Sadler PJ
    Chemistry; 2004 Oct; 10(20):5173-9. PubMed ID: 15372674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA interactions of monofunctional organometallic ruthenium(II) antitumor complexes in cell-free media.
    Novakova O; Chen H; Vrana O; Rodger A; Sadler PJ; Brabec V
    Biochemistry; 2003 Oct; 42(39):11544-54. PubMed ID: 14516206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kinetics of aquation and anation of ruthenium(II) arene anticancer complexes, acidity and X-ray structures of aqua adducts.
    Wang F; Chen H; Parsons S; Oswald ID; Davidson JE; Sadler PJ
    Chemistry; 2003 Dec; 9(23):5810-20. PubMed ID: 14673852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Organometallic osmium(II) arene anticancer complexes containing picolinate derivatives.
    van Rijt SH; Peacock AF; Johnstone RD; Parsons S; Sadler PJ
    Inorg Chem; 2009 Feb; 48(4):1753-62. PubMed ID: 19146436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of organometallic ruthenium-arene anticancer drugs that resist hydrolysis.
    Ang WH; Daldini E; Scolaro C; Scopelliti R; Juillerat-Jeannerat L; Dyson PJ
    Inorg Chem; 2006 Oct; 45(22):9006-13. PubMed ID: 17054361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 58.